Some venture capital firms are striking deals claiming a percentage of royalties, as Aisling Capital and Clarus Ventures recently did with Pharmacyclics' tyrosine kinase inhibitor ibrutinib. "[T]he royalty play illustrates the 'new normal' in life sciences VC investing: a search for investments with short time horizons; a lack of faith in preclinical or even phase I molecules and the teams developing them; and an irresistible pull to 'sure-fire' deals of a more financial nature," writes CBT Advisors CEO Steve Dickman.
Biotech venture capitalists take the royalties route
SmartBrief Job Listings for Health Care
|Compliance and Ethics Director||
Sysmex America, Inc.
|Director, Site Quality Management||
|Palm Springs, CA|
|Compliance Officer-Medical Products||
W. L. Gore